Sunil Tani: started new data

2026-04-17T04:54:04Z

started new data

New page

{{Short description|Indian pharmaceutical company}}
{{Infobox company
| name = Neuland Laboratories
| logo =
| trading_name = [[National Stock Exchange of India|NSE]]: [https://www.nseindia.com/get-quotes/equity?symbol=NEULANDLAB NEULANDLAB]<br>[[Bombay Stock Exchange|BSE]] : [https://www.bseindia.com/stock-share-price/neuland-laboratories-ltd/neulandlab/524558/ 524558]
| type = [[Public limited company|Public]]
| founded = January 7 1984
| founders =
| hq_location_city = [[Hyderabad]]
| hq_location_country = [[India]]
| num_locations =
| num_locations_year =
| area_served = [[North America]], [[Switzerland]], [[United Kingdom|UK]], [[Germany]], [[Italy]] and the [[Netherlands]] and 80 more countries.
| key_people = Dr. Davuluri Rama Mohan Rao (Executive Chairman)<br>D. Sucheth Rao (Executive Vice Chairman)<br>D. Saharsh Rao (Chief Executive Officer & Managing Director)
| industry = [[Contract manufacturing organization|CDMO]]
| num_employees = ~2,000 (including 360+ scientists) <ref>{{cite web |title=Neuland Laboratories Limited – Q1 FY26 Investor Presentation |url=https://www.neulandlabs.com/sites/neulandlabs/files/neuland-labs/Investors/investor-presentations/2025-26/NLL_Q1FY26_InvestorPresentationvF.pdf |access-date=February 14, 2026}}</ref>
| num_employees_year =
| parent =
| website = {{URL|http://www.neulandlabs.com}}
}}

'''Neuland Laboratories Limited''' is an Indian publicly listed [[Contract manufacturing organization|contract development and manufacturing organization]] (CDMO) headquartered in Hyderabad.<ref>{{Cite web |title=Buy, Sell or Hold: Nuvama initiates coverage on Neuland Laboratories; Motilal Oswal maintains buy on L&T Finance |url=https://m.economictimes.com/markets/stocks/news/buy-sell-or-hold-nuvama-initiates-coverage-on-neuland-laboratories-motilal-oswal-maintains-buy-on-lt-finance/articleshow/123689639.cms |access-date=2025-10-06 |website=The Economic Times}}</ref> Founded in 1984, the company produces [[Active ingredient|active pharmaceutical ingredients]] (APIs), advanced intermediates, and peptide APIs.<ref>{{cite news |date=12 May 2025 |title=Market master Vijay Kedia’s 2 favourite stocks: Must-know holdings for smart investors |url=https://www.financialexpress.com/market/stock-insights/market-master-vijay-kedias-2-favourite-stocks-must-know-holdings-for-smart-investors/3840593/ |work=Financialexpress |language=en}}</ref> Its shares are traded on the [[Bombay Stock Exchange]] and the [[National Stock Exchange of India|National Stock Exchange]].<ref>{{cite news |last1=Laboratories |first1=Neuland |title=Why Neuland Laboratories shares fall 7% in trade? check reasons here |url=https://www.business-standard.com/markets/news/neuland-labs-down-7-after-0-7-million-shares-change-hands-via-block-deals-124121200215_1.html |work=www.business-standard.com}}</ref><ref>{{cite news |title=Neuland appoints Parag Deshmukh as SVP – Head of Manufacturing |url=https://www.indianpharmapost.com/people/neuland-appoints-parag-deshmukh-as-svp-head-of-manufacturing-16933 |work=www.indianpharmapost.com/}}</ref>

== Overview ==

Neuland operates through two primary business verticals: Generic Drug Substances (GDS) and CDMO services. Its operations span process research and development, custom synthesis, scale-up, regulatory documentation support, and commercial manufacturing.<ref>{{cite web |title=CDMO Services |url=https://www.neulandlabs.com/en/cdmo-services |website=Neuland Laboratories |access-date=17 February 2026}}</ref>

The company exports products to more than 80 countries and maintains approvals from major international regulatory authorities, including the [[USFDA|United States Food and Drug Administration (US FDA)]], European Directorate for the Quality of Medicines (EDQM), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).<ref>{{cite web |title=Annual Report 2024–25 |url=https://www.neulandlabs.com/sites/neulandlabs/files/neuland-labs/Investors/annual-reports/2024-25/Neuland_Annual_Report_2024-25.pdf |website=Neuland Laboratories |access-date=17 February 2026}}</ref>

As of 2025, Neuland employs approximately 2,000 people, including over 360 scientists engaged in research and development activities.<ref>{{cite web |title=Investor Presentation – Corporate Overview |url=https://www.neulandlabs.com/en/investors/investor-presentations |website=Neuland Laboratories |access-date=17 February 2026}}</ref>
==Product development==
The company's operations are divided into three segments: Custom Manufacturing Solutions, which develops APIs from pre-clinical to commercial stages; Generic Drug Substances, which manufactures non-exclusive APIs; and a Peptide API unit that specializes in peptide synthesis.<ref name=":0">{{Cite web |title=Neuland Laboratories |url=https://trendlyne.com/visitor/loginmodal.html?next=/research-reports/stock/933/NEULANDLAB/neuland-laboratories-ltd/ |website=HDFC securities}}</ref>

== Facilities ==
Neuland Laboratories operates multiple world-class facilities supporting active pharmaceutical ingredient (API), intermediate, and peptide production.

* '''Unit I – Bonthapally''': The primary manufacturing hub situated in Bonthapally village, Medak District, Telangana, with multiple production blocks including kilo labs and quality assurance laboratories. It holds approvals from major regulatory agencies and supports commercial API production. <ref>{{cite web |title=Unit I – Bonthapally |url=https://www.neulandlabs.com/en/about-us/our-facilities/unit-i-bonthapally |access-date=February 14, 2026}}</ref>
* '''Unit II – Pashamylaram''': A large-scale manufacturing facility comprising multiple production blocks, an engineering workshop, and warehouses. <ref>{{cite web |title=About Us – Our Facilities |url=https://www.neulandlabs.com/en/about-us/our-facilities |access-date=February 14, 2026}}</ref>
* '''Unit III – Gaddapotharam''': A multi-product facility designed for advanced intermediates and APIs, with analytical development and pilot plant capabilities. <ref>{{cite web |title=Unit III – Gaddapotharam |url=https://www.neulandlabs.com/en/about-us/our-facilities/unit-iii-gaddapotharam |access-date=February 14, 2026}}</ref>
* '''R&D Centre – Bonthapally''': Research and development centre with a team of approximately 360 scientists, pilot labs, and analytical capabilities to catalyze process development and technology transfer. <ref>{{cite web |title=R&D Centre – Our Facilities |url=https://www.neulandlabs.com/en/about-us/our-facilities/rd-centre |access-date=February 14, 2026}}</ref>

== Upcoming Peptide Facility ==
The new peptide facility at the company’s 17‑acre Bonthapally campus in Hyderabad is expected to become operational by summer 2026, supporting increased production capacity to address growing global demand for complex peptides, including GLP‑1 therapies.<ref>{{Cite web |date=2026-03-09 |title=Neuland Labs to Add Commercial Peptide Capacity with New India Facility in 2026 |url=https://www.contractpharma.com/breaking-news/neuland-labs-to-add-commercial-peptide-capacity-with-new-india-facility-in-2026/ |access-date=2026-04-15 |website=Contract Pharma |language=en-US}}</ref>

The new peptide manufacturing facility will feature digitalized operations supported by distributed control system (DCS) automation and electronic batch‑record platforms. It is also designed with expanded purification and drying infrastructure, including multi‑column preparative HPLC systems, large‑scale lyophilizers, enhanced solvent‑handling capabilities, and upgraded waste‑management processes. These features are intended to support consistent batch quality and more efficient production cycles.<ref>{{Cite web |last=Sternberg |first=Charlie |date=2026-03-09 |title=Neuland Labs to Add Commercial Peptide Capacity with New India Facility in 2026 |url=https://www.contractpharma.com/breaking-news/neuland-labs-to-add-commercial-peptide-capacity-with-new-india-facility-in-2026/ |access-date=2026-04-15 |website=Contract Pharma |language=en-US}}</ref>

==References==
{{Reflist}}

[[Category:Pharmaceutical companies]]
[[Category:Laboratories in India]]
[[Category:Contract development and manufacturing organizations]]
[[Category:Health care companies of India]]
[[Category:Companies based in Hyderabad, India]]

Neuland Laboratories - Revision history

Sunil Tani: started new data